Glioblastoma: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 8,230 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

  NCT06325683· National Cancer Institute (NCI)· Updated 3 Nov 2026

  “Scheduled Interim Monitoring”Registry text, quoted unchanged. Source

• Terminated

  Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma

  NCT04590664· Emory University· Updated 28 Oct 2026

  “PI Decision”Registry text, quoted unchanged. Source

• Terminated

  Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma

  NCT04019002· Susan Chang· Updated 27 Oct 2026

  “Slow Accrual”Registry text, quoted unchanged. Source

• Terminated

  Radioimmunotherapy With Lu-177 Labeled 6A10 Fab-fragments in Patients With Glioblastoma After Standard Treatment

  NCT05533242· University Hospital Muenster· Updated 13 Oct 2026

  “The remaining shelf-life of 1 component used in the manufacture of the study medication (SM) was insufficient to support further study conduct, and no additional material could be manufactured. Production of a new SM is planned for further projects.”Registry text, quoted unchanged. Source

• Withdrawn

  Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients

  NCT06964815· Istituto Oncologico Veneto IRCCS· Updated 2 Oct 2026

  “It was noted that, from a methodological standpoint, it would be advisable to use a drug with a marketing authorization (MA) in order to more appropriately assess the treatment's efficacy, which is the study's primary endpoint.”Registry text, quoted unchanged. Source

• Suspended

  Glioblastoma Remote Monitoring and Care - Research Protocol

  NCT06129760· Case Comprehensive Cancer Center· Updated 15 Sept 2026

  “PI decision”Registry text, quoted unchanged. Source

• Suspended

  Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

  NCT06329570· NaviFUS Corporation· Updated 9 Sept 2026

  “FDA reviewing”Registry text, quoted unchanged. Source

• Suspended

  Methimazole in Patients With Progressive Glioblastoma

  NCT05607407· Case Comprehensive Cancer Center· Updated 17 Aug 2026

  “On hold per study team”Registry text, quoted unchanged. Source

• Withdrawn

  Magnetic Resonance Fingerprinting Guided Extended Resection in Glioblastomas

  NCT06455189· Case Comprehensive Cancer Center· Updated 1 Jul 2026

  “Terminated IRB”Registry text, quoted unchanged. Source

• Terminated

  CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma

  NCT05627323· Chimeric Therapeutics· Updated 29 Jun 2026

  “IND application withdrawn”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

  NCT05432804· National Cancer Institute (NCI)· Source

• PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

  NCT06161519· National Cancer Institute (NCI)· Source

• Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme

  NCT00083512· National Cancer Institute (NCI)· Source

• Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

  NCT03919071· National Cancer Institute (NCI)· Source

• Leica Microsystems Sponsored PMCF Study to Collect and Confirm Clinical Data on the Performance of the GLOW400 Device When Used in Accordance With Its Intended Use

  NCT07366892· Leica Microsystems (Schweiz) AG· Source

• Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

  NCT06325683· National Cancer Institute (NCI)· Source

• Fimepinostat in Treating Brain Tumors in Children and Young Adults

  NCT03893487· Sabine Mueller, MD, PhD· Source

• Clinical and translational controlled study of Perampanel treatment around Surgery in patients with progressive glioblastoma (PerSurge)

  2023-503938-52-00· Universitaetsklinikum Heidelberg AöR· Source

• Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma

  NCT06896110· Andrew P. Groves· Source

• Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

  NCT04216329· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 93
• Organoids 33
• Mendelian Randomization Analysis 14
• CRISPR-Cas Systems 11
• Gene Expression Profiling 150
• Sequence Analysis, RNA 10
• Exome Sequencing 2
• Proteomics 47
• Metabolomics 21
• Mass Spectrometry 9
• Flow Cytometry 16
• Immunohistochemistry 22
• Liquid Biopsy 10
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 224
• Positron-Emission Tomography 35
• Magnetic Resonance Imaging 231
• Machine Learning 265
• Deep Learning 42
• Cohort Studies 54
• Genome-Wide Association Study 13

See which targets of this disease your abstract mentions, and go to the people working on them.